Skip to main content
SpringerLink
Log in

Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to assess the prognostic factors of peripheral T-cell lymphoma, unspecified (PTCL-U).

Patients and methods

We retrospectively analyzed 30 cases fulfilling the criteria of PTCL-U defined by the World Health Organization classification. The patients were treated with 6–8 cycles of a CHOP or THP (pirarubicin)-COP regimen.

Results

A high serum sIL-2R level (≥2,000 U/ml) at onset was associated with a low complete remission rate. Patients with high sIL-2R had significantly lower survival rates (5 year, 15.1%) than those with low sIL-2R (<2,000 U/ml) (100%) (P < 0.005). Factors associated with worse overall survival in a univariate analysis were high sIL-2R (P < 0.005), high age (>60 years) (P < 0.05), poor performance status (P < 0.01) and poor international prognostic index (P < 0.05). No correlation was observed between sIL-2R and other markers. Multivariate analysis showed that only sIL-2R was a prognostic factor for overall survival (P < 0.01).

Conclusion

The results suggest that a high serum sIL-2R level predicts a poor prognosis in PTCL-U.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J et al (2000) Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96:1921–1925

    PubMed  CAS  Google Scholar 

  • Cantrell DA, Smith KA (1983) Transient expression of interleukin 2 receptors. Consequences for T cell growth. J Exp Med 158:1895–1911. doi:10.1084/jem.158.6.1895

    Article  PubMed  CAS  Google Scholar 

  • Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244–1253

    PubMed  CAS  Google Scholar 

  • Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F, Cortelazzo S, Rigacci L, Devizzi L, Todeschini G, Santini G, Brugiatelli M, Federico M (2004) Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474–2479. doi:10.1182/blood-2003-09-3080

    Article  PubMed  CAS  Google Scholar 

  • Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Brière J, Haioun C et al (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 92:76–82

    PubMed  CAS  Google Scholar 

  • Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M et al (2005) Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol 131:73–79. doi:10.1007/s00432-004-0600-9

    Article  PubMed  CAS  Google Scholar 

  • Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S et al (2006) Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma. Eur J Haematol 77:217–225. doi:10.1111/j.1600-0609.2006.00702.x

    Article  PubMed  CAS  Google Scholar 

  • Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P et al (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: updated results of the prospective study LNH87–2. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 15:1131–1137

    PubMed  CAS  Google Scholar 

  • Hara T, Tsurumi H, Takemura M, Goto H, Yamada T, Sawada M et al (2000) Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin’s lymphoma. Am J Hematol 64:257–261. doi:10.1002/1096-8652(200008)64:4<257::AID-AJH4>3.0.CO;2-2

    Article  PubMed  CAS  Google Scholar 

  • Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835–3849

    PubMed  CAS  Google Scholar 

  • Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K et al (1997) Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529–534. doi:10.1056/NEJM199708213370804

    Article  PubMed  CAS  Google Scholar 

  • Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF et al (1998) C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin’s lymphoma. Leuk Lymphoma 31:351–357

    PubMed  CAS  Google Scholar 

  • Miller AA, Salewski E (1994) Prospects for pirarubicin. Med Pediatr Oncol 22:261–268. doi:10.1002/mpo.2950220410

    Article  PubMed  CAS  Google Scholar 

  • Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, Honma Y (1999) Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin’s lymphoma. Blood 94:3541–3550

    PubMed  CAS  Google Scholar 

  • Niitsu N, Okamoto M, Okabe-Kado J, Takagi T, Yoshida T, Aoki S et al (2001) Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. Blood 97:1202–1210. doi:10.1182/blood.V97.5.1202

    Article  PubMed  CAS  Google Scholar 

  • Niitsu N, Honma Y, Iijima K, Takagi T, Higashihara M, Sawada U et al (2003) Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin’s lymphoma. Leukemia 17:196–202. doi:10.1038/sj.leu.2402699

    Article  PubMed  CAS  Google Scholar 

  • Ogata K, Yokose N, An E, Kamikubo K, Tamura H, Dan K et al (1996) Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome. Br J Haematol 93:45–52. doi:10.1046/j.1365-2141.1996.4641003.x

    Article  PubMed  CAS  Google Scholar 

  • Preti HA, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R (1997) Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 127:186–194

    PubMed  CAS  Google Scholar 

  • Robb RJ (1982) Human T-cell growth factor: purification and interaction with a cellular receptor. Lymphokine Res 1:37–43

    PubMed  CAS  Google Scholar 

  • Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R et al (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135:3172–3177

    PubMed  CAS  Google Scholar 

  • Salven P, Teerenhovi L, Joensuu H (1999) A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin’s lymphoma. Blood 94:3334–3339

    PubMed  CAS  Google Scholar 

  • Sasaki K, Niitsu N (2000) Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin’s lymphoma. Eur J Haematol 65:195–202. doi:10.1034/j.1600-0609.2000.065003195.x

    Article  PubMed  CAS  Google Scholar 

  • Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H et al (2002) A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin’s lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 68:354–361. doi:10.1034/j.1600-0609.2002.01654.x

    Article  PubMed  CAS  Google Scholar 

  • Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M et al (1999) International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin’s lymphomas: report of the jury. J Clin Oncol 17:423–429

    PubMed  CAS  Google Scholar 

  • Stasi R, Zinzani PL, Galieni P, Lauta VM, Damasio E, Dispensa E et al (1994) Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin’s lymphoma. Br J Haematol 88:770–777. doi:10.1111/j.1365-2141.1994.tb05116.x

    Article  PubMed  CAS  Google Scholar 

  • Takagi T, Oguro M (1987) (2″-R)-4′-o-tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol 20:151–154. doi:10.1007/BF00253970

    Article  PubMed  CAS  Google Scholar 

  • The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994. doi:10.1056/NEJM199309303291402

    Article  Google Scholar 

  • Tsurumi H, Yamada T, Sawada M, Kasahara S, Kanemura N, Kojima Y et al (2004) Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 130:107–113. doi:10.1007/s00432-003-0508-9

    Article  PubMed  CAS  Google Scholar 

  • Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M et al (2007) A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol 25:107–114. doi:10.1002/hon.815

    Article  PubMed  CAS  Google Scholar 

  • Wasik MA, Vonderheid EC, Bigler RD, Marti R, Lessin SR, Polansky M et al (1996) Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Arch Dermatol 132:42–47. doi:10.1001/archderm.132.1.42

    Article  PubMed  CAS  Google Scholar 

  • Zaja F, Russo D, Silvestri F, Fanin R, Damiani D, Infanti L et al (1997) Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome. Haematologica 82:171–177

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan

    Jun-ichi Kitagawa, Takeshi Hara, Hisashi Tsurumi, Naoe Goto, Nobuhiro Kanemura, Senji Kasahara, Toshiki Yamada, Michio Sawada, Masahito Shimizu & Hisataka Moriwaki

  2. Division of Hematology, Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu, 500-8513, Japan

    Takeshi Yoshikawa & Takeshi Takahashi

  3. Department of Immunopathology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan

    Tsuyoshi Takami

Authors
  1. Jun-ichi Kitagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeshi Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hisashi Tsurumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naoe Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nobuhiro Kanemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takeshi Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Senji Kasahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Toshiki Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michio Sawada
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takeshi Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masahito Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tsuyoshi Takami
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hisataka Moriwaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hisashi Tsurumi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kitagawa, Ji., Hara, T., Tsurumi, H. et al. Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U). J Cancer Res Clin Oncol 135, 53–59 (2009). https://doi.org/10.1007/s00432-008-0440-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-008-0440-0

Keywords

Search

Navigation